Scarica l'app Stockscreener
3.35
0.15%
0.005
Dopo l'orario di chiusura:
3.32
-0.03
-0.90%
Precedente Chiudi:
$3.345
Aprire:
$3.37
Volume 24 ore:
57,347
Relative Volume:
0.77
Capitalizzazione di mercato:
$53.26M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.1703
EPS:
-19.67
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
+0.75%
1M Prestazione:
-2.33%
6M Prestazione:
+21.82%
1 anno Prestazione:
-2.33%
Intervallo 1D:
$3.32
$3.50
Intervallo di 1 settimana:
$3.06
$3.50
Portata 52W:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Confronta PYPD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.35 | 53.10M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
How to build a custom watchlist for PolyPid Ltd.2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
What indicators show strength in PolyPid Ltd.Short Setup & Free Technical Pattern Based Buy Signals - newser.com
How to use a screener to detect PolyPid Ltd. breakoutsMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com
An Overlooked Crisis in Hospitals Could Be Pharma's Next Great Opportunity - MarketScreener
Weiss Ratings Reaffirms Sell (E+) Rating for PolyPid (NASDAQ:PYPD) - MarketBeat
Analyzing recovery setups for PolyPid Ltd. investors2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is this a good reentry point in PolyPid Ltd.2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Best data tools to analyze PolyPid Ltd. stockMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Increase in Short Interest - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - MarketBeat
Price action breakdown for PolyPid Ltd.July 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Will PolyPid Ltd. see short term momentumBuy Signal & Stock Portfolio Risk Management - newser.com
Tools to monitor PolyPid Ltd. recovery probabilityBreakout Watch & Safe Capital Investment Plans - newser.com
Is PolyPid Ltd a good long term investmentMid Cap Growth Trends & Achieve Consistent Profits - earlytimes.in
PolyPid to present phase 3 SHIELD II trial results at ACS congress - Investing.com Nigeria
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 By Investing.com - Investing.com Australia
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 - Investing.com India
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - The Manila Times
PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative
PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire
Key Phase 3 Trial Results: PolyPid's D-PLEX₁₀₀ for Surgical Infection Prevention at Major Surgery Congress - Stock Titan
PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON) Head to Head Survey - Defense World
What analysts say about PolyPid Ltd stockVolume Analysis Techniques & Invest Smarter With Data-Driven Models - earlytimes.in
What drives PolyPid Ltd stock priceFibonacci Retracement Levels & Free Rapid Growing Investment Returns - earlytimes.in
PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus PT from Analysts - Defense World
PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen - MarketBeat
What to expect from PolyPid Ltd. in the next 30 days2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9%Time to Buy? - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9% – Time to Buy? - Defense World
Will a bounce in PolyPid Ltd. offer an exitBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Multi factor analysis applied to PolyPid Ltd.Exit Point & Verified High Yield Trade Plans - newser.com
Real time breakdown of PolyPid Ltd. stock performanceMarket Rally & AI Driven Price Predictions - newser.com
Does PolyPid Ltd. show high probability of reboundExit Point & Safe Entry Trade Signal Reports - newser.com
Strategies to average down on PolyPid Ltd.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
PolyPid completes Israeli Ministry of Health GMP inspection - MSN
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - msn.com
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):